ArticleThe Journal of cell biology1997
Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors.
Article in The Journal of cell biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.
- PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets.BMC cancer · 2020Pooled it
- A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (humPcMab-60) Demonstrated Antitumor Efficacy in Pancreatic and Colorectal Cancer Xenograft Models.Antibodies (Basel, Switzerland) · 2025Article
- Tenascin-C regulates CXCR4Frontiers in immunology · 2025Article
- CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression.Cancer research · 2024Article
- Podocalyxin promotes the formation of compact and chemoresistant cancer spheroids in high grade serous carcinoma.Scientific reports · 2024Article
- Visualization of choroidal vasculature in pigmented mouse eyes from experimental models of AMD.Experimental eye research · 2024Article
- A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.International journal of molecular sciences · 2023Article
- The Immunological Capacity of Thrombocytes.International journal of molecular sciences · 2023Review
- A tumor-restricted glycoform of podocalyxin is a highly selective marker of immunologically cold high-grade serous ovarian carcinoma.Frontiers in oncology · 2023Article
- Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models.Frontiers in oncology · 2022Article
- Podocalyxin in Normal Tissue and Epithelial Cancer.Cancers · 2021Review
- A cancer-specific anti-podocalyxin monoclonal antibody (60-mGBiochemistry and biophysics reports · 2020Article
- In vivo generation of haematopoietic stem/progenitor cells from bone marrow-derived haemogenic endothelium.Nature cell biology · 2019Article
- Application of miR-193a/WT1/PODXL axis to estimate risk and prognosis of idiopathic membranous nephropathy.Renal failure · 2019Article
- Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-2.Biochemistry and biophysics reports · 2018Article
- Determination of critical epitope of PcMab-47 against human podocalyxin.Biochemistry and biophysics reports · 2018Article
- Article
- Podocalyxin as a major pluripotent marker and novel keratan sulfate proteoglycan in human embryonic and induced pluripotent stem cells.Glycoconjugate journal · 2017Review
- PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2017Article
- Podocalyxin as a major pluripotent marker and novel keratan sulfate proteoglycan in human embryonic and induced pluripotent stem cells.Glycoconjugate journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
MEP21 is an avian antigen specifically expressed on the surface of Myb-Ets-transformed multipotent hematopoietic precursors (MEPs) and of normal thrombocytes. Using nanoelectrospray tandem mass spectrometry, we have sequenced and subsequently cloned the MEP21 cDNA and named the gene thrombomucin as it encodes a 571-amino acid protein with an extracellular domain typical of the mucin family of proteoglycans. Thrombomucin is distantly related to CD34, the best characterized and most used human hematopoietic stem cell marker. It is also highly homologous in its transmembrane/intracellular domain to podocalyxinlike protein-1, a rabbit cell surface glycoprotein of kidney podocytes. Single cell analysis of yolk sac cells from 3-d-old chick embryos revealed that thrombomucin is expressed on the surface of both lineage-restricted and multipotent progenitors. In the bone marrow, thrombomucin is also expressed on mono- and multipotent progenitors, showing an overlapping but distinct expression pattern from that of the receptor-type stem cell marker c-kit. These observations strengthen the notion that the Myb-Ets oncoprotein can induce the proliferation of thrombomucin-positive hematopoietic progenitors that have retained the capacity to differentiate along multiple lineages. They also suggest that thrombomucin and CD34 form a family of stem cell-specific proteins with possibly overlapping functions in early hematopoietic progenitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.